TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
Abstract
Prior neoadjuvant trials with 12 weeks of dual anti-HER2 therapy without chemotherapy demonstrated a meaningful pathologic complete response (pCR) in patients with HER2-positive breast cancer. In this trial, we sought to determine whether longer treatment would increase the rate of pCR.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 14, 2020
- Source ID
- 10.1158/1078-0432.ccr-19-0851
Entities
People
- Andres Forero
- Anna Maria V. Storniolo
- Anne Pavlick
- Antonio C. Wolff
- Brent N. Rexer
- C. Kent Osborne
- Carmine De Angelis
- Carolina Gutierrez
- Ian Krop
- Jamunarani Veeraraghavan
- Julie R. Nangia
- Matthew P Goetz
- Mothaffar F Rimawi
- Polly Niravath
- Rachel Schiff
- Rita Nanda
- Sao Jiralerspong
- Susan Hilsenbeck
- Tao Wang
Organizations
- Baylor College of Medicine
- National Cancer Institute